

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q75927

Ryuichi MORISHITA, et al.

1.53(b) Continuation Appln. of
Application No: 09/660,522

Confirmation No.: Not yet assigned

Group Art Unit: 1636 (prior application)

Filed: July 9, 2003

Examiner: D. Lambertson (prior application)

For: MEDICAMENT COMPRISING HGF GENE

PRELIMINARY AMENDMENT

MAIL STOP NON-FEE AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SUBSTITUTE SPECIFICATION:

Amend the substitute specification by inserting before the first line the sentence:

--This is a continuation of Application No. 09/660,522, filed September 12, 2000, which is a continuation of Application No. 09/029,497 filed February 26, 1998; which is a 371 National Stage Application of PCT/JP96/02359 filed August 22, 1996, the disclosures of which are incorporated herein by reference.--

Please amend paragraph 27, bridging pages 7 and 8 as follows:

Where the HGF gene is introduced into, e.g., cells, the growth of vascular endothelial cells is accelerated, while undesired growth of vascular smooth muscle cells is not accelerated, as